Amphotericin B

Generic Name: Amphotericin B

Brand Names: Abelcet, Ambisome, Amphotec, Fungizone

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₇₃NO_₁₇

CAS Number: 1397-89-3

Unique Ingredient Identifier: 7XU7A7DROE

Background: Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL...

Indication: Used to treat potentially life threatening fungal infections.

Associated Conditions: Coccidioidomycosis, Fungal Infections, Histoplasmosis, Invasive Aspergillosis, Invasive Fungal Infections, Leishmaniasis, Meningitis, Cryptococcal, Meningitis, Fungal, Mucocutaneous Leishmaniasis, Mycotic endophthalmitis, Penicillium marneffei infection, Visceral Leishmaniasis, Candidal cystitis, Disseminated Cryptococcosis, Fungal osteoarticular infections, Ocular aspergillosis, Refractory aspergillosis, Severe Coccidioidomycosis, Severe Cryptococcosis, Severe Fungal infection caused by Basidiobolus spp., Severe Fungal infection caused by Conidiobolus spp., Severe Fungal infection caused by sporotrichosis spp., Severe Histoplasmosis, Severe Mucocutaneous leishmaniasis, Severe North American blastomycosis, Severe Systemic candidiasis

Associated Therapies: -

Clinical Trials

SCH708980 With and Without AmBisome for Visceral Leishmaniasis

Phase 1

Withdrawn

Conditions: Leishmaniasis
Effects of Immunotherapy

Interventions: Drug: SCH708980 Anti-IL-10 monoclonal
Drug: AmBisome

First Posted Date: 2011-09-20

Last Posted Date: 2013-08-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01437020

Locations: 🇮🇳
Kala-Azar Medical Research Center (KAMRC), Rambag Road, Muzaffarpur, India
🇮🇳
Banaras Hindu University, Varanasi, India

Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil

Phase 4

Terminated

Conditions: Visceral Leishmaniasis

Interventions: Drug: Liposomal amphotericin B
Drug: amphotericin B deoxycholate
Drug: Antimoniate of N-methylglucamine

First Posted Date: 2011-03-08

Last Posted Date: 2017-09-05

Lead Sponsor: University of Brasilia

Target Recruit Count: 378

Registration Number: NCT01310738

Locations: 🇧🇷
Hospital Universitário da Universidade Federal de Sergipe, Sergipe, Aracaju, Brazil
🇧🇷
Hospital de Doencas Infecto Contagiosas - HDIC, Teresina, Piaui, Brazil
🇧🇷
Hospital São José de Doenças Infecciosas, Fortaleza, Ceará, Brazil

and more 2 locations

Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients

Phase 4

Completed

Conditions: Liver Disease
Fungal Infection

Interventions: Drug: Anidulafungin
Drug: Liposomal amphotericin B

First Posted Date: 2011-02-24

Last Posted Date: 2014-05-30

Lead Sponsor: Fundacion SEIMC-GESIDA

Target Recruit Count: 61

Registration Number: NCT01303549

Locations: 🇪🇸
Hospital de Bellvitge, Barcelona, Spain
🇪🇸
Hospital Vall d'Hebrón, Barcelona, Spain
🇪🇸
Hospital Clinic i Provincial, Barcelona, Spain

and more 9 locations

Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Invasive Fungal Disease

Interventions: Drug: Placebo
Drug: Liposomal amphotericin B

First Posted Date: 2010-12-14

Last Posted Date: 2015-05-07

Lead Sponsor: Gilead Sciences

Target Recruit Count: 355

Registration Number: NCT01259713

Locations: 🇬🇧
Gilead Sciences, Cambridge, United Kingdom

Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh

Phase 3

Completed

Conditions: Visceral Leishmaniasis

Interventions: Drug: Miltefosine + Paromomycin
Drug: Liposomal amphotericin B
Drug: liposomal amphotericin B + paromomycin
Drug: liposomal amphotericin B + miltefosine

First Posted Date: 2010-05-13

Last Posted Date: 2016-01-21

Lead Sponsor: Drugs for Neglected Diseases

Target Recruit Count: 602

Registration Number: NCT01122771

Locations: 🇧🇩
Bhaluka UZHC, Bhaluka, Mymensingh, Bangladesh
🇧🇩
Gaffargaon, Gaffargaon, Mymensingh, Bangladesh
🇧🇩
Community Based Medical College, Trishal, Mymensingh, Bangladesh

and more 1 locations

Liver Transplant European Study Into the Prevention of Fungal Infection

Phase 3

Completed

Conditions: Liver Transplantation
Mycoses

Interventions: Drug: micafungin
Drug: fluconazole
Drug: liposomal amphotericin B
Drug: caspofungin

First Posted Date: 2010-01-28

Last Posted Date: 2024-11-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 350

Registration Number: NCT01058174

Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation

Phase 4

Conditions: Invasive Pulmonary Aspergillosis

First Posted Date: 2009-09-30

Last Posted Date: 2009-09-30

Lead Sponsor: Capital Medical University

Target Recruit Count: 400

Registration Number: NCT00986713

Locations: 🇨🇳
Beijing Chaoyang Hospital,Affiliate of Capital Medical University, Beijing, Beijing, China

High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals

Phase 1

Completed

Conditions: Cryptococcal Meningitis
HIV Infections

Interventions: Drug: Fluconazole
Drug: Amphotericin B

First Posted Date: 2009-04-22

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 168

Registration Number: NCT00885703

Locations: 🇺🇬
Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site, Kampala, Uganda
🇿🇦
Durban International Clinical Research Site CRS, Durban, KwaZulu-Natal, South Africa
🇺🇸
University of Southern California CRS, Los Angeles, California, United States

and more 7 locations